Is Leap Therapeutics Inc (LPTX) a Stock to Watch After Losing -2.82% This Week?

Leap Therapeutics Inc (LPTX) stock is lower by 2.82% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Leap Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on LPTX!

See Full LPTX Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With LPTX Stock Today?

Leap Therapeutics Inc (LPTX) stock is lower by -2.21% while the S&P 500 is up 0.27% as of 11:03 AM on Tuesday, Jul 11. LPTX has fallen -$0.07 from the previous closing price of $3.17 on volume of 48,710 shares. Over the past year the S&P 500 is higher by 14.71% while LPTX has fallen -75.20%. LPTX lost -$7.57 per share in the over the last 12 months.

More About Leap Therapeutics Inc

Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P100, P102, P204,and P205. Click Here to get the full Stock Report for Leap Therapeutics Inc stock.